#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Current state of surgical treatment of cancer of the stomach and gastro-esophageal junction in the Czech Republic


Authors: M. Duda 1,3;  L. Dušek 2;  T. Jínek 3;  L. Adamčík 3;  M. Škrovina 3
Authors‘ workplace: II. chirurgická klinika Lékařské fakulty Univerzity Palackého a Fakultní nemocnice Olomouc 1;  Institut biostatiky a analýz Masarykova univerzita Brno 2;  Chirurgické oddělení nemocnice a Komplexního onkologického centra Nový Jičín 3
Published in: Rozhl. Chir., 2018, roč. 97, č. 7, s. 309-319.
Category: Original articles

Overview

Introduction:

Analysis of the epidemiology and treatment of cancer of the stomach (CS) and gastro-esophageal junction (GEJ) in the Czech Republic (CR).

Method:

Analysis from the National Cancer Registry (NCR) of the CR examined data up to the year 2013.

Results:

In CS and GEJ, the incidence is 14.3, mortality is 10.5 and prevalence is 51.1 per 100,000 population. The Karlovy Vary, Olomouc and Moravian-Silesian regions had the highest incidences. The median age at diagnosis is 69 years for men and 72 years for women. Location in the stomach prevails in 85% of the patients, cancer of the gastric cardia occurring in 15%. In men, this ratio is 81 to 19%, in women 90 to 10%. The disease is usually diagnosed late; in 2013, 36% of CS and 32% of GEJ tumors were stage I and II. 53% of CS and 56% of tumors of the GEJ were diagnosed as stage III and IV, and in 11% and 12%, the stage was not determined. In the years 2009–2013 (1,580 patients with CS and GEJ), only 22% were treated surgically, surgery and oncological treatment was given to 21.3%, only non-surgical treatment was received by 15.7% and 41% of patients received no oncological treatment. Overall five-year survival in patients treated between 2010 and 2013 was 32%. At stage I it was 69%, at stage II 41%, at stage III 23% and at stage IV it was 6%. Five-year survival rates according to disease stage and type of treatment given and median of survival were analysed on 8,348 patients with CS and GEJ between 2004 and 2013. Surgery only was performed in 4,116 patients, surgery and radiotherapy was administered to 113 patients, surgery and chemotherapy to 1,855 patients, and 1,125 patients received chemotherapy alone. In 98% of the treated patients, chemotherapy and/or radiotherapy was administered adjuvantly after the surgery. Primary operations were performed at a total of 175 surgical centers, only 22 of them performing more than 10 operations annually. The median of survival differed depending on the number of operations performed: at enters performing more than 20 operations, the median was 24.8 months (m); at enters performing 10–19 operations, the median was 18.2 m; at centers performing 6–9 operations the median was 18.1 m; and at centers performing less than 6 operations, the median was 13.1 m.

Conclusion:

Early diagnosis is key for five-year survival. Treatment is based on surgery; greatest improvement is seen when surgery is combined with chemoradiotherapy, which is usually administered adjuvantly in the CR. At stage I in CS +9.5%, GEJ cancer +26.5%, at stage II in CS +14.7%, GEJ cancer +16.4% and at stage III in CS +13.3%, GEJ cancer +2.6%. Palliative chemo and/or radiotherapy does not prolong five-year survival and must be selected on an individual basis with regard to the expected benefit for the patient. Facilities performing a greater number of surgical procedures have better long-term results.

Key words:

malignant esophageal tumors – epidemiology – treatment – results


Sources
  1. Rapant V. (Ed.) Rakovina žaludku a kardie. Praha, SZdN 1956.
  2. Duda M, Neoral Č. Chirurgie horní části zažívacího traktu (chirurgie foregutu) (Editorial). Rozh Chir 2018;97, v tisku.
  3. Siewert JR, Hölscher AH, Becker K, et al. Kardiocarcinom: Versuch einer therapeutisch relevanten Klassifikation. Chirurg 1987;58:25−32.
  4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med 2006;355:11−20.
  5. Chua YJ, Cunningham D. The UK NVRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: Implications for clinical practice. Ann Sur Oncol 2007;14:2687−90.
  6. Boige V, Pignon J, Saint-Aubert B, Lasser P, et al. Final results of a randomized trial comparing preoperative S-fluorouracil(F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus ACCORD study. J Clin Oncol 2007;25(18S):4510.
  7. Obermannová R, Novák J, Novotný I, et al. Multidisciplinární přístup v diagnostice a léčbě karcinomu žaludku. Gastroent Hepatol 2013;67:390−5.
  8. Obermannová R. Současné postavení systémové chemoterapie v léčbě karcinomu žaludku – přínos, či zhoršení kvality života? Klin Onkol 2016;29:245−6.
  9. Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;110:189−94.
  10. Modrá kniha České onkologické společnosti. Brno, Masarykův onkologický ústav 2017.
  11. Brenkman HJ, Haverkamp L, Ruurda JP, et al. Worldwide practice in gastric cancer surgery. World J Gastroenterol 2016;22:4041−8.
  12. Šmíd D, Skalický T, Fichtl J, et al. Vliv paliativní chemoterapie na kvalitu života nemocných s karcinomem žaludku. Klin Onkol 2016;29:279−86.
  13. Coupland VH, Lagergren J, Lüchtenborg M, et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004–2008. Gut 2013;62:961–6.
  14. Dikken JL, Stiekema J, van de Velde CJ, et al. Quality of care indicators for the surgical treatment of gastric cancer: a systematic review. Ann Surg Oncol 2013;20:381–98.
  15. Dikken JL, Wouters MW, Lemmens VE, et al. Influence of hospital type on outcomes after oesophageal and gastric cancer surgery. Br J Surg. 2012;99:954–63.
  16. Anderson O, Ni Z, Møller H, et al. Hospital volume and survival in oesophagectomy and gastrectomy for cancer. Eur J Cancer 2011;47:2408–12.
  17. Jensen LS, Nielsen H, Mortensen PB, et al. Enforcing centralization for gastric cancer in Denmark. Eur J Surg Oncol 2010;36(Suppl.1):S50−54.
  18. Wahnschaff F, Clauer U, Roder J. Surgery of gastric cancer in a medium volume center. Chirurg 2012; 83:823−9.
  19. Reavis KM, Hinojosa MW, Smith BR, et al. Hospital volume is not a predictor of outcomes after gastrectomy for neoplasm. Am Surg 2009;75:932−6.
Labels
Surgery Orthopaedics Trauma surgery
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#